GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » ROIC %

Akoya Biosciences (Akoya Biosciences) ROIC % : -46.35% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Akoya Biosciences's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -46.35%.

As of today (2024-05-16), Akoya Biosciences's WACC % is 12.73%. Akoya Biosciences's ROIC % is -72.89% (calculated using TTM income statement data). Akoya Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Akoya Biosciences ROIC % Historical Data

The historical data trend for Akoya Biosciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences ROIC % Chart

Akoya Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-24.64 -20.73 -66.41 -98.10 -72.74

Akoya Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.34 -88.77 -97.57 -58.61 -46.35

Competitive Comparison of Akoya Biosciences's ROIC %

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akoya Biosciences's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's ROIC % falls into.



Akoya Biosciences ROIC % Calculation

Akoya Biosciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-56.032 * ( 1 - -0.06% )/( (79.103 + 75.042)/ 2 )
=-56.0656192/77.0725
=-72.74 %

where

Akoya Biosciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-35.288 * ( 1 - 0.2% )/( (76.918 + 75.042)/ 2 )
=-35.217424/75.98
=-46.35 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akoya Biosciences  (NAS:AKYA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Akoya Biosciences's WACC % is 12.73%. Akoya Biosciences's ROIC % is -72.89% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Akoya Biosciences ROIC % Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akoya Biosciences (Akoya Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.
Executives
Brian Mckelligon director, officer: President/CEO 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla officer: Chief Operating Officer C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler director C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin director, 10 percent owner C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler director
Jennifer Kamocsay officer: General Counsel 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll officer: Chief Financial Officer 5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d. director 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry officer: Chief Medical Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy officer: Chief People Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d officer: Chief Business Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752

Akoya Biosciences (Akoya Biosciences) Headlines